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Abstract
Gene-based tests of association are frequently applied to common SNPs (MAF.5%) as an alternative to single-marker tests.
In this analysis we conduct a variety of simulation studies applied to five popular gene-based tests investigating general
trends related to their performance in realistic situations. In particular, we focus on the impact of non-causal SNPs and a
variety of LD structures on the behavior of these tests. Ultimately, we find that non-causal SNPs can significantly impact the
power of all gene-based tests. On average, we find that the ‘‘noise’’ from 6–12 non-causal SNPs will cancel out the ‘‘signal’’
of one causal SNP across five popular gene-based tests. Furthermore, we find complex and differing behavior of the
methods in the presence of LD within and between non-causal and causal SNPs. Ultimately, better approaches for a priori
prioritization of potentially causal SNPs (e.g., predicting functionality of non-synonymous SNPs), application of these
methods to sequenced or fully imputed datasets, and limited use of window-based methods for assigning inter-genic SNPs
to genes will improve power. However, significant power loss from non-causal SNPs may remain unless alternative statistical
approaches robust to the inclusion of non-causal SNPs are developed.
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of subjects is possible in some situations, for many diseases it is
difficult to obtain a sufficient number of cases.
One promising approach to address these limitations of
traditional, agnostic, single marker analyses of SNP microarray
data considers testing biologically meaningful sets of SNPs. The
two main purposes of this approach are to gain power through (1)
aggregating true genotype-phenotype signal across the members of
the set and (2) reducing the multiple-testing penalty by reducing
the number of tests of significance being conducted. A number of
recent approaches for the analysis of common variant SNP data
using sets of SNPs have been proposed [2–5]. See Petersen, Spratt
and Tintle for a more comprehensive listing.[6] Notably, there are
similarities between this approach and the approach being
proposed for the analysis of rare variants from next-generation
sequencing data [7,8].
While SNP-set methods have frequently been cited in the
methodological literature as improving power relative to singlemarker tests, in practice, these methods have remained somewhat
under-utilized. Much of the literature for SNP-set testing methods
applied to common and/or rare variants has considered the
question of how to aggregate SNP genotype-phenotype signals
statistically and which approaches are most powerful. Less focus
has been given to the question of how SNPs should be aggregated
into sets. While there are numerous biologically relevant sets (e.g.
pathways, genes), we will focus the remainder of our attention on
gene-based sets since, to date, this is arguably the most common
way to aggregate SNPs. As would be expected, in most situations

Introduction
Increasingly, in the analysis of SNP microarray data, SNPs are
aggregated into sets representing genes, pathways, or other
biologically meaningful sets. Set-based tests are then conducted
in addition to testing for genotype-phenotype association using
single marker approaches. The set-based approach is part of a
general trend in statistical genetics to leverage a priori biological
knowledge in the analysis of genetic data, instead of conducting
analyses in an agnostic (no prior biological knowledge considered)
fashion. However, the traditional, single-marker, agnostic approach toward the analysis of SNP microarray data is by far the
most commonly used. In the single-marker approach, researchers
typically test each of the 1 million-plus measured or imputed SNPs
for evidence of independent association with the phenotype after
controlling for relevant covariates. A substantial multiple-testing
penalty (e.g., p,161028) is then applied to each of the singlemarker association test p-values, before deeming a SNP as showing
significant evidence of a genotype-phenotype association. With
such a small type I error cutoff for statistical significance, designing
an adequately powered study can be challenging. Additionally,
results to date suggest generally low effect sizes with an average
OR of 1.3 in the NHGRI GWAS catalog [1] for most common
SNPs (MAF.5%). Thus, in order to have adequate power to find
disease associated SNPs, very large sample sizes are needed –
especially for SNPs with lower minor allele frequencies, e.g. 5–
10%. While designing studies with tens to hundreds of thousands
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Figure 1. Heatmap of LD structure used in realistic data analysis. Figure 1 shows a heatmap illustrating the complex LD structure utilized in
the realistic data analysis. The ,900 kb region includes an approximately 400 kb ‘‘gene’’ flanked by approximately 250 kb of inter-genic space on
each side. There are a total of 80 common SNPs (MAF.0.05) in the region, denoted by line which indicate their location in the genome. The six causal
SNPs in our analysis are indicated in bold. All other SNPs are non-causal. There is a large, moderate-strong LD block on the upper end of the gene,
which crosses from inside the gene into the inter-genic space. Other LD is fairly localized to small blocks.
doi:10.1371/journal.pone.0062161.g001

gene-based tests of association assign all SNPs within a gene
(intragenic SNPs) to that gene for the test.
Methods vary, however, when considering inter-genic SNPs
(SNPs that exist outside of the start and stop positions of a gene’s
exonic and intronic regions). The most common approach to
assign SNPs to genes is the ‘‘Window’’ approach. In essence, the
window approach extends the start and stop positions of the gene
an arbitrary amount, ranging from 5 to 500 kb. Typically the
window size is the same for both ends of a gene, but it can differ
[9]. Rules vary in regards to handling windows that contain other
genes. For example, Wang et al. [10] assign each SNP to its
nearest gene, as long as that SNP is within 500 kb of the gene.
Thus, while SNPs could be assigned to genes up to 500 kb away,
the window size is actually much smaller for most genes. Others
have used a fixed window approach that assigns all SNPs within
50 kb of the gene. Thus SNPs that are intragenic to other genes, or
in intergenic regions not flanked by the gene of interest, could be
assigned to a gene [11]. In addition to window-type approaches for
assigning SNPs to genes, some authors have only used intragenic
SNPs in their analysis [12,13]. Finally, a few authors have
considered assigning intergenic common SNPs to genes if the SNP
falls within an LD block spanning the gene (e.g., all SNPs in LD
above a certain threshold with SNPs in the gene) [14].
Additionally, others have considered a hybrid approach combinPLOS ONE | www.plosone.org

ing a small window plus intergenic SNPs in LD with SNPs inside
of the gene [15].
To date, little work has considered the pros and cons of the
various SNP-gene assignment approaches and their potential
impact on the performance of gene-based tests. We consider the
impact of the inclusion of non-causal SNPs and LD structure on
set-based tests of association for common SNP variants using
simulated genotype and phenotype data. In each of these
scenarios, we consider five SNP-set tests of association, representing two broad classes of tests [6] allowing us to investigate the
differential impact of non-causal SNP inclusion and LD structure
on these methods. Three tests we consider attempt to combine
single-marker p-values into a single set-based p-value, while
accounting for LD structure: the GATES method [4] and two
different versions of the VEGAS procedure [3]. We also
considered two regression based approaches (traditional logistic
regression and logistic regression using principal components) that
operate on the full genotype-phenotype matrix [5].

Methods
In order to assess the impact of different methods of assigning
SNPs to genes on gene-based tests of association, we simulated
genotype and phenotype data. In the following paragraphs we

2

May 2013 | Volume 8 | Issue 5 | e62161

Assigning SNPs to Genes in Tests of Association

Table 1. Relationship of Power to Independent Non-Causal and Causal SNPs1,2.

Gene-Based Test

Estimated absolute power loss for one
additional non-causal SNP#

Estimated absolute power gain for
one additional causal SNP

Estimated number of non-causal
SNPs which cancel out the power
gained from one causal SNP

GATES

0.0025

0.0160

6.3

VEGAS-SUM

0.0028

0.0299

10.6

VEGAS-MAX

0.0025

0.0151

6.1

LR-PC

0.0023

0.0267

11.5

LR

0.0027

0.0305

11.4

1

Using a multiple regression model including all parameter and simulation results.
Assuming all other parameters are held constant.
doi:10.1371/journal.pone.0062161.t001
2

describe the data simulation process. There were four separate
genotype simulations conducted as part of this analysis: (1) A
simulation of independent genotypes; (2) A simulation of genotypes
with LD between non-causal variants only; (3) A simulation of
genotypes with LD between causal and non-causal variants; and
(4) A realistic genotype simulation involving complex LD
structure. In all cases, in order to generate the samples used in
the analysis, a large population of genotypes was simulated
assuming HWE. Five hundred random case-control samples were
generated for each simulation setting.

SNPs in the set. For each of the 32 causal SNP settings, we
considered 9 different non-causal SNP settings (0,2,4,8 or 32 noncausal SNPs at either 5% or 30% MAF), for a total of 288
( = 9632) total settings. To simulate a situation with no LD, all
SNP genotypes were simulated independently.

Simulating genotypes with LD between non-causal SNPs
Genotypes were also simulated to include LD structure between
the non-causal SNPs. Specifically, non-causal SNP genotypes were
recreated for each of the settings described in the previous section,
assuming all non-causal SNPs were in the same LD block, or one
of two separate LD blocks. LD blocks were in either low
(correlation, r, of 0.5 between all pairs of SNPs in the block) or
high (correlation, r, of 0.9 between all pairs of SNPs in the block)
correlation. SNP genotypes were generated using the method of
simulating correlated binary variables [16].
A total of 896 simulation settings were considered. The settings
were closely related to those used for the simulation with no LD.
Specifically, the same 32 combinations of parameters for causal
SNPs were used, along with the same options for non-causal SNPs

Simulation of genotypes with no LD
The simulation with no LD covered 288 separate settings, as
follows. Sets of SNP genotypes contained 1, 2, 4, or 8 causal SNPs.
The relative risk (defined later) of each SNP set was 1.25 or 2.00,
the total sample size (split evenly between cases and controls) was
either 2000 or 4000, and the causal SNPMAF was either 5% or
30%. Thus, there were a total of different ways to generate causal

Figure 2. Power loss from the inclusion of non-causal SNPs
with complex LD structure using a window approach to include
inter-genic SNPs. Figure 2 illustrates the power loss observed for all
five tests in the realistic LD structure simulation, as more and more noncausal SNPs are added to the test. In particular, a notable decline in
power is noted for all tests as the number of intra-genic and inter-genic
non-causal SNPs increases. The notable exception is when a small
increase in power is observed for most tests when a small region
(window) outside of the gene is included since two causal SNPs are
located nearby to the gene. Power loss from the inclusion of non-causal
SNPs can be substantial, in particular the inclusion of intra-genic noncausal SNPs substantially decreases power. Thus, using increasingly
large windows only decreases power when no causal SNPs are located
far from the gene.
doi:10.1371/journal.pone.0062161.g002

PLOS ONE | www.plosone.org

Figure 3. Power loss from the inclusion of non-causal SNPs
with complex LD structure using an LD approach to include
inter-genic SNPs. Figure 3 illustrates behavior observed for different
methods when using an LD aware approach to assigning inter-genic
SNPs to genes. In particular, an LD-aware approach limits the number of
inter-genic SNPs assigned to the set, which reduces the number of noncausal SNPs assigned to the set if no causal SNPs are located outside of
the gene. While GATES, LR and LR-PC showed improved power from the
LD-aware approach, VEGAS-sum illustrated a loss in power from the
addition of non-causal SNPs in LD with causal intra-genic SNPs.
doi:10.1371/journal.pone.0062161.g003
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total of 96 simulation settings, representing all possible combinations of settings above ( = 3 [# of causal SNPs = 1,2,4] 62 [# of
non-causal SNPs = 4,8] 62 [relative risk = 1.25,2] 62 [sample
size = 2000,4000] 62 [MAF = 0.05,0.30] 62 [levels of LD = high,
low]). In addition to analyzing all SNPs in the set, we also
conducted analyses which ignored all causal SNPs to represent a
situation where only tag SNPs were measured, for a total of 192
( = 2696) settings analyzed when LD was present between causal
and non-causal SNPs.

Simulation of realistic LD structure
We also used the observed LD structure in a sample of real
genotype data as a starting point for simulation. We started by
inferring phased haplotypes and population haplotype frequencies
in a ,900 kb region using fastPHASE [17]. These population
estimates were then used to generate random pairs of haplotypes –
representing a population of genotypes. The simulated realistic
genotype data represents 80 unique SNPs spanning MAFs from
0.06 to 0.50 (mean = 0.33 sd = 0.15). We arbitrarily let the
(approximately) middle 400 kb represent a gene, with approximately 250 kb of intergenic space on either side of the gene.
Figure 1 illustrates the start-stop positions of the gene, the locations
of the measured genotypes in and nearby to the gene, and the LD
structure (r2) in the genotype sample.
As shown in Figure 1, 33 SNPs are contained within the gene
(intragenic) and 47 SNPs are in the regions outside of the gene
(intergenic with 23 on one side and 24 on the other). Figure 1 also
illustrates (in bold) the locations of 6 SNP loci (4 intragenic and 2
intergenic) denoted as ‘‘causal’’ in our simulation. Thus of the 33
intragenic SNPS, 29 are non-causal and 4 are causal, while of the
47 intergenic SNPs, 2 are causal and 45 are non-causal. For the
realistic genotypes, we considered four different relative risks (1.25,
1.5, 2.0, and 3.0) and sample sizes of 1000 and 2000 evenly split
between cases and controls, for a total of 8 simulation settings. As
is described further in the results section, we applied window and
LD approaches to include or exclude different combinations of
causal and non-causal SNPs.

Figure 4. Manhattan plot for region in and around VSTM4.
Figure 4 illustrates the –log10 tranformed p-values located within 50 kb
of VSTM4. We see two distinct regions containing small p-values: (a) a
region near 49,970,000 shows 3 SNPs with transformed p-values greater
than 2.3 (p-value,0.005), and another region between 49,998,000 and
49,999,000 (overlapping VSTM4) also has three SNPs with transformed
p-values greater than 2.3.
doi:10.1371/journal.pone.0062161.g004

with the added component that non-causal SNPs were either all in
the same high or low LD block, or non-causal SNPs were evenly
split between two separate high, low or high and low LD blocks.

Simulating genotypes with LD between non-causal and
causal SNPs
We also considered LD structure between causal and noncausal SNPs. In this scenario, we assumed each causal SNP was in
its own LD block, and that each non-causal SNP was in exactly
one LD block with a causal SNP. For each LD block, every noncausal SNP was correlated with the causal SNP to the same degree
(either r = 0.5 or r = 0.9) and all non-causal SNPs within the block
had the minimum correlation possible with each other (i.e. r = 0.25
for low-LD blocks and r = 0.81 for high-LD blocks There were a

Phenotype simulation for simulated genotypes
Disease status was simulated following a method similar to that
of Li and Leal [7]. Specifically, each causal SNP in the set was
assigned a separate disease prevalence, computed as P(DU) = 0.10/
i, to represent that SNP’s unique contribution to overall disease
prevalence, where i = the number of causal SNPs. Overall disease

Table 2. P-values from individual and SNP-set approaches for the VSTM4 gene.

Region (SNP-set)

Total Number
of SNPs

Additional SNPs with
p-value less than
0.002 (p-value)1
GATES

VEGAS-SUM

VEGAS-MAX

LR-PC

LR

VSTM4

5

rs12245255 (0.00016)

0.0006

0.0034

0.011

0.0021

0.02

VSTM4+/25kb

6

rs4298825 (0.003)
rs4488117 (0.002)

0.0011

0.0023

0.035

0.0046

0.14

VSTM4+/210kb

10

rs6537494 (0.0016)

0.0014

0.0014

0.060

0.0047

0.20

VSTM4+/215kb

15

rs4240498 (0.0008)
rs7074818 (0.0016)

0.0020

0.0007

0.16

0.013

0.22

VSTM4+/225kb

25

none

0.0030

0.0010

0.24

0.015

0.12

VSTM4+/250kb

38

none

0.0034

0.0024

0.33

0.041

0.003

1. To find the total number of significant SNPs in each SNP-set include all significant SNPs located in and above the row of interest.
doi:10.1371/journal.pone.0062161.t002
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Table 3. LD (r2) between most 6 associated SNPs (p,0.005 from individual marker tests).

Location (bp dow
nstream of VSTM4)

SNPID

rs7074818

rs4240498

rs6537494

rs4298825

rs4488117

rs12245255

11696

rs7074818

1.00

0.90

0.94

0.37

0.38

0.84

10038

rs4240498

0.90

1.00

0.96

0.37

0.40

0.90

9824

rs6537494

0.94

0.96

1.00

0.40

0.41

0.90

2915

rs4298825

0.37

0.37

0.40

1.00

0.94

0.42

312

rs4488117

0.38

0.40

0.41

0.94

1.00

0.45

Intragenic

rs12245255

0.84

0.90

0.90

0.42

0.45

1.00

doi:10.1371/journal.pone.0062161.t003

and traditional logistic regression [5]. In the following paragraphs
we briefly describe the five methods.

prevalence, P(D), is approximately 10% in all cases, since
(12P(DU))i is approximately equal to 0.10 for all i = 1,2,4,8.
The probability of disease given an observed genotype at each
causal SNP can then be simulated using a Bernoulli random
variable for each causal SNP, with probability P(DU/Gj) (G is the
genotype at the site of interest, and takes values of G = 0,1,2
representing the number of minor (risk) alleles) and where
conditional disease probabilities are computed as: P(D/
G = 0) = P(DU)/[(12m)2+2cm(12m)+(2c21)m2],
P(D/G = 1) =
cP(D/G = 0) and P(D/G = 2) = (2c21) P(D/G = 0) and where m
is the MAF at the site, and we assume an additive disease model
with relative risk, c. If any of the causal SNP sites yield a ‘‘disease’’
status using the Bernoulli random variable, the person is deemed
diseased. As noted earlier, large sets of genotypes were simulated
acting as a large population, case/control status is simulated as
described above, and then the appropriate number of cases and
controls are randomly chosen from this population of all
genotypes.

GATES
The GATES method [4] is an extension of a Simes approach to
combining multiple single marker genotype-phenotype tests
applied at each SNP. Briefly, the method computes a standard
linear trend test of association for each SNP with the disease
phenotype, yielding a p-value for each SNP in the set. LD between
the genotypes of all SNPs in the set is computed based on the
sample. The individual SNP p-values are then combined
(summed) in a manner which appropriately controls for the
correlation structure – namely, small p-values from multiple highly
correlated SNPs count less than small p-values from multiple noncorrelated SNPs.

VEGAS (VEGAS-SUM and VEGAS-MAX)
The VEGAS procedure [3] also combines individual SNPphenotype statistics from a standard linear trend test of
association. Without linkage disequilibrium, the sum of these
statistics has a null distribution of chi-square with n degrees of
freedom, where n equals the number of SNPs in the SNP set. To
account for linkage disequilibrium, the VEGAS procedure uses a
Monte Carlo approach with simulations from a multivariate
normal to estimate the null distribution. First, a vector of
independent standard Normal random variables is generated
and multiplied by the Cholesky decomposition matrix of the
matrix of pairwise LD values. Each element of the vector is then
squared. This process is repeated and the gene-based statistic is
calculated for each vector generating a null distribution. Two
different gene-based statistics are suggested: the sum statistic
(VEGAS-SUM), which is the sum of the chi-square SNP statistics,
and the max statistic (VEGAS-MAX), which is the maximum of
the chi-square SNP statistics. The gene-based p-value is simply the
proportion of times the simulated gene test statistic exceeds the
observed gene test statistic.

SNP-set tests
All simulated data was analyzed using five recently proposed
SNP-set tests, namely GATES [4], two different versions of
VEGAS [3], logistic regression using principal components [5],

Logistic regression using Principal Components (LR-PC)
Gauderman et al. [5] proposed a modified logistic regression
approach to SNP set testing. First, principal components analysis is
applied to the matrix of genotypes represented by all SNPs in the
set. The first X principal components are retained, where X is the
minimum set of principal components that explains at least 80% of
the variability in genotypes. Logistic regression is then used to
regress the disease phenotype onto the minimal set of X principal
components. The gene-based p-value is calculated from comparing this model to the null model using a likelihood ratio test.

Figure 5. Relationship of LD block size and structure to window
size from HapMap data. Figure 5 illustrates that as distance from the
gene increases, the likelihood that a SNP is in LD with an intra-genic
SNP decreases. Importantly, the likelihood of a SNP being in moderate
LD (r2.0.70) more than10 kb from the boundary of the gene is only
approximately 35%, with the likelihood of being in high LD even lower.
doi:10.1371/journal.pone.0062161.g005
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Logistic regression (LR)

Changes in power when LD is present between noncausal SNPs

Gauderman et al. [5] also considered logistic regression applied
directly to the genotype matrix. Here, each SNP is its own
explanatory variable in the logistic regression model and a genebased p-value is computed using a likelihood ratio test.

Next, we considered the impact of LD between the non-causal
SNPs. The LD simulation parameters we added to the model were
amount of LD (r = 0.5 or r = 0.9) and the number of LD blocks
within the non-causal SNPs (1 or 2). Regression models similar to
those described in the previous section were used to assess overall
trends in power as related to the simulation parameters. Overall,
the eight main effects terms explained most of the observed
variability in power (model r2 values ranged from 44% to 67%).
The six main effects described in the previous section behaved the
same in all cases (detailed results not shown), and so we focus our
attention only on the two LD parameters.
For all five tests, power decreased very little when moving from
one to two LD blocks; the main effect term in each of the
regression models was non-significant. On the other hand, the
amount of LD observed (high or low) was significantly related to
the observed power of the test in three of the five models, though
the direction of effect was different for different tests. For the
GATES test, high LD between non-causal SNPs yielded
significantly more power than low LD. A similar trend was
observed for LR, though it was not statistically significant. For
both VEGAS-max and VEGAS-sum increased LD was associated
with significantly lower power. The LR-PC test performed very
poorly in situations with high-LD and a large number of noncausal SNPs. Further investigation found that this approach was
eliminating the causal variants from the analysis since principal
components on the genotype matrix found more than 80% of the
correlation in genotypes explained by non-causal variants alone.
Figures S1–S5 illustrate the typical behavior of these tests.
Importantly, these trends mean that the GATES test is more
robust to the inclusion of non-causal variants, when those variants
are in LD, while the VEGAS tests are less robust to the presence of
non-causal variants in the presence of non-causal LD.

Real data
As part of our evaluation of the performance of different SNPset methods, we also extended a previous analysis by our group to
an analysis of heart disease causing SNPs in the Framingham heart
study sample. Details of the sample, genotyping technology and
gene assignments are provided elsewhere [18]. We focused our
analysis on a gene (VSTM4) on chromosome 10 which showed
modest evidence of association in single marker analyses. The full
dataset is currently available viadbGaP (http://www.ncbi.nlm.nih.
gov/gap).

HapMap data
In order to discuss the practical implications of our simulation
analyses in situations where genome-wide application of SNP-set
tests will occur, we explored SNP data as provided by HapMap.
Specifically, we considered the Phase 3 CEU HapMap (HapMap
3 draft release #2, NCBI B36) sample, representing individuals of
northern and western European ancestry [19]. SNPs were then
classified as being intragenic (located within a protein-encoding
gene; 577,306 SNPs) or intergenic (located in an intergenic region
within 200 kb of a protein encoding gene; 488,942 SNPs) based on
gene locations identified by Ensembl [20]. LD data on all
HapMap SNPs is provided by HapMap for SNPs within 200 kb of
each other.

Results
Changes in power when no LD is present
We first consider the 288 simulation settings for which there is
no LD between SNPs. We summarized the general impact of
simulation parameters on power through the use of a multiple
regression model predicting power by each of the 6 simulation
parameters as main effects (relative risk, number of causal SNPs,
number of non-causal SNPs, MAF of causal SNPs, MAF of noncausal SNPs, and sample size). A separate model was fit for each of
the five gene-based testing methods. Main effects models yielded r2
values between 63% and 66%, suggesting that the main effects
terms capture much of the observed variation in power values.
As expected, for all five tests, as the relative risk, sample size, or
MAF of causal SNPs increased, the power of all tests significantly
increased with similar estimated regression coefficients across the
five methods (details not shown). The MAF of non-causal SNPs
was not significantly related to power for any test except LR-PC,
where power decreased as the MAF of non-causal SNPs increased.
Changes in power across the other two simulation settings, the
number of causal and non-causal SNPs, are the focus of our
analysis here. First, for all five tests, as the number of non-causal
SNPs increased, power decreased; while power increased with the
addition of causal SNPs to the analysis. For all of our simulation
settings, and averaged across the five SNP test sets, power declined
by an average absolute amount of 0.0026 for each additional noncausal SNP included in the test, but can be as high as 0.0095.
Table 1 indicates the average values for each of the five tests; little
variation between tests was observed. The ratio of power gain for
causal SNPs to power loss for non-causal SNPs provides a rough
estimate of the number of non-causal SNPs that ‘‘cancel out’’ the
effect of a single causal variant. As shown in Table 1, these ratios
range from 6.1 to 11.5 for the five tests.
PLOS ONE | www.plosone.org

Power change in the presence of LD between causal and
non-causal SNPs
Next, we considered the impact of LD between causal and noncausal SNPs. Regression models similar to those described in
previous sections were used to assess overall trends in power in
relation to the simulation parameters. Overall, the seven main
effects terms explained most of the observed variability in power
(model r2 values ranged from 64% to 87%). Most simulation
parameters described earlier (sample size, RR, MAF, number of
causal SNPs) behaved similarly here, so we focus our discussion
only on the amount of LD and the number of non-causal SNPs.
When analyzing all SNPs simultaneously (causal and noncausal), the addition of non-causal SNPs was not related to
changes in power for four of the five methods. The lone exception
was VEGAS-max which yielded lower power with larger numbers
of non-causal SNPs. We note that in all simulation settings
considered in this analysis, all non-causal SNPs are in LD with a
causal SNP. As seen earlier when investigating the relationship
between power and amount of LD, different methods yielded
different results. In this case, three of the five methods (GATES,
VEGAS-sum and LR) showed significant power gain with higher
levels of LD, while VEGAS- max showed significant power loss
with higher levels of LD, while LR-PC showed an insignificant
change in power.
A follow-up analysis which considered only non-causal SNPs in
order to illustrate a situation where causal SNPs were not
genotyped (e.g., if only using tagSNPs) showed similar patterns
of association in almost all cases. The two exceptions were that the
6
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VEGAS-max test no longer showed significant power loss as LD
increased, and the LR-PC test showed significant power gain as
LD increased.

15kb are included – which includes all 6 SNPs showing the
strongest Table 3 illustrates the LD structure between the 6 most
significant SNPs and suggests some LD between the two regions.
We note that none of the 38 individual SNP p-values would yield
evidence of association strong enough to be considered genomewide significant (p,161028), and only two would be significant at
a Bonferroni corrected significance level for the 38 SNPs in this
region (0.05/38 = 0.0013; rs12245255 and rs4240498). The set
methods (especially VEGAS-SUM) provide robust evidence of
association in this region.

Power change in a realistic LD situation
We now focus on how power changes for the different tests in a
realistic LD situation (as depicted Figure 1). The focus of our
analysis will be to evaluate the performance of the window and LD
approaches for this data (see Introduction for details). As we have
shown, the inclusion of non-causal SNPs can create significant
power loss in many situations. Notably, within the ‘‘gene’’ there
are 29 non-causal SNPs and 4 causal SNPs. Thus, even without
adding any intergenic SNPs there are a large number of noncausal SNPs that will decrease power for the resulting tests of
association. At window sizes of 50 kb, 100 kb, 150 kb and 250 kb,
there were 3, 12, 29 and 35 non-causal SNPs added to the test,
respectively. Note that there are two causal SNPs nearby to the
gene, but outside of the gene boundaries (one upstream, and one
downstream of the gene).
Figure 2 illustrates similar trends to those seen earlier, namely as
the number of non-causal SNPs increases, power decreases. As
noted in the previous paragraph, as the window size increases, the
number of non-causal SNPs included in the analysis also increases
– decreasing power. We also illustrate two analyses where we did
not include some or all intragenic non-causal SNPs in the analysis
(all 29 dropped, or 14 of 29 dropped) to illustrate how better prior
knowledge about which SNPs are causal can improve power.
While Figure 2 illustrates only a specific simulation setting
(prevalence = 10%, Risk = 2, Sample size = 1000), other
simulation settings showed results (detailed results not shown). In
particular, aside from VEGAS-MAX which performed poorly in
the presence of strong LD, all tests showed decreasing power from
the inclusion of non-causal SNPs, and increased power from the
inclusion of causal SNPs (e.g., the ‘‘bump’’ seen when moving
from 4 to 6 causal SNPs).
We also considered the inclusion of intergenic regions around
the SNP using a combined window-LD thresholding approach. In
particular, only SNPs within a given window of the gene that
exhibited LD of at least r2.0.7 with at least one SNP in the gene
were included in the analysis. Figure 3 illustrates the results of this
analysis for a particular simulation setting (similar results were seen
for other settings). In particular, note that for three of the four tests
(GATES, LR, and LR-PC) power increases with this approach.
Power increases occur because the inclusion of the intergenic noncausal SNPs yield a stronger signal due to LD with intergenic
causal SNPs. For VEGAS-sum, the power decreased because, as
noted earlier, adding non-causal variants in LD tends to decrease
power for VEGAS-sum. Results for VEGAS-max are not shown
due to its poor performance.

Consideration of real LD structure
To provide a genome-wide view of the LD structure as it
pertains to gene-based tests of association, we analyzed the LD
structure of HapMap data. Figure 5 illustrates how LD structure
relates to window size. As expected, blocks of high LD are of
limited size, and so as distance from the end of the gene increases,
the likelihood of an intergenic SNP being in LD with a SNP in the
gene, declines dramatically.

Discussion
Gene-based tests are being applied with increasing frequency to
common SNPs (MAF.5%) directly measured by SNP microarrays or imputed in GWAS as an alternative to single-marker
tests. Despite the promise that aggregating the signal from multiple
causal variants will improve power and reduce multiple testing
penalties, these methods have generally performed poorly in
practice. In our analysis we investigated a variety of realistic factors
potentially associated with power across two major classes of genebased tests. First, we confirmed that all gene-based tests considered
here illustrate well-known and expected relationships between
power and sample size, relative risk, MAF and number of causal
variants. Furthermore, we found that the inclusion of non-causal
variants was detrimental to power for all methods. In fact, on
average, it only took 6–12 independent non-causal variants to
‘‘cancel out’’ the effect of a single causal variant. This implies that
unless more than 10–15% of all independent variants are causal,
gene-based tests of common variants may be relatively ineffective.
Complex LD structure, the differing behavior of different
statistical methods to that LD structure, and variations in the
impact of relative risk/MAF/sample size means that we should be
hesitant to generalize that result to all situations. However, the fact
remains that non-causal SNPs are substantially impacting power of
gene-based tests.
The impact of non-causal SNPs is compounded when we
consider that many investigators include inter-genic SNPs in genebased analyses. If no causal SNPs are present in the inter-genic
space, then researchers should only include inter-genic SNPs that
are in LD with SNPs inside the gene – and, in this case, it is only
beneficial for certain methods (e.g., GATES, LR), while this
approach appears detrimental to other methods (e.g., VEGAS). As
more and more genomic information becomes available, utilizing
LD information in gene-based tests is becoming more practical
than ever.
Window-based approaches are only reasonable when causal
SNPs are in the inter-genic space. Of course, a priori, researchers
do not know if causal SNPs are being included. However,
increasingly, bioinformatics databases include annotations of intergenic spaces (e.g., locations of regulatory elements) that can be
used intelligently when adding inter-genic SNPs. Blind use of the
window approach can no longer be recommended as best practice.
But, if window-based approaches are to be used to capture LD
structure, only very small windows should be used since, as shown

Performance of methods on real data
We applied GATES, VEGAS-SUM, VEGAS-MAX, LR-PC
and LR to sets of SNPs in and around VSTM4, a 13 kb gene
located at approximately 49.9Mb on chromosome 10. Figure 4
shows two distinct regions containing SNPs with small p-values.
Table 2 shows the results of the five different SNP-set methods
applied to the 5 SNPs within VSTM4, as well as to sets of SNPs
using windows of increasing size. The VEGAS-MAX and LR
methods yield relatively large p-values across the different sets, as
compared to the other methods. The LR-PC and GATES
methods both show the strongest association for the 5 SNPs
within VSTM4, with slowly increasing p-values as more and more
SNPs are added to the set. The VEGAS-SUM statistic shows the
strongest evidence for association of the set when SNPs within
PLOS ONE | www.plosone.org
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in Figure 4, a very small percentage of SNPs beyond 10 kb are in
moderate to high LD with SNPs in the gene. We acknowledge that
this approach will ignore regulatory elements located more than
10 kb from the gene. Further analysis is needed to explore
distributions of gene sizes, SNP distributions, and regulatory
elements in order to further refine these general guidelines.
However, perhaps even more importantly than SNPs in the
inter-genic space, is the impact that better prioritization of
intragenic SNPs will have on power. For example, as we anticipate
more and more sequence data available, we can anticipate that (a)
all causal SNPs will be typed and (b) that predicted functional
impact of SNPs can be integrated into the analysis. For example,
given exonic sequence data, it may be practical to include only
non-synonymous inter-genic SNPs in the analysis, thus increasing
the causal to non-causal SNP ratio and, potentially, improving
statistical power. Additionally, if all SNPs are typed (directly
sequenced or imputed), then we longer will need to rely on tag
SNPs (non-causal SNPs in LD with causal SNPs) to capture the
causal signal. Further consideration is needed to explore how
gene-based tests should be applied to common variants when
investigating sequence data.
Recently, given the advent of next-generation sequencing data,
gene-based testing methods which incorporate both common and
rare variants have been proposed. Further work is needed to see
how the conclusions found here apply to those methods. However,
the effect of non-causal variants is likely the same since methods
which focus only on rare variants have been shown to suffer power
loss in the presence of non-causal variants (e.g., Li and Leal 2008).
Ultimately, methods are needed which are more robust to the
inclusion of non-causal variants. A promising approach has
recently been proposed by Liu et al. (unpublished manuscript).
As more knowledge of ‘‘typical’’ genetic architectures becomes
available, more sophisticated analyses comparing single and
multiple marker methods will be possible that can explicitly
consider the tradeoff of multiple testing penalties for power in the
presence of differing numbers of causal variants, their relative risks
and allele frequency distribution, as well as the impact of noncausal variants.
Lastly, our analysis considers only five of a very large, and
growing, set of gene-based tests. Notably, we only considered selfcontained tests and did not consider competitive tests in our
analysis. We use the GATES/VEGAS tests as representatives of

tests that combine single marker p-values and use LD structure to
account for correlation between genotypes. LR and LR-PC were
selected as representatives of gene-based tests requiring the full
genotype-phenotype matrix and use regression or regression-like
approaches to assess significance of a set of markers. Given the
disparate relationships between LD structure and power, even
between the methods selected here mean that some caution is
needed when projecting our conclusions beyond these methods.
Our analysis suggests that one reason for the poor performance
of gene-based tests of association for common variants is due to
limited power in the presence of a large percentage of non-causal
variants. This finding suggests that window-based methods of
assigning SNPs to genes should not be used, especially in light of
increasing knowledge of the human genome. Methods are needed
which are more robust to the inclusion of non-causal variants,
though better a priori prediction of causal variants using
bioinformatics methods will also substantially improve power.

Supporting Information
Power loss from the inclusion of noncausal SNPs with LD between non-causal SNPs. Figures S1–S5 illustrate power loss for the GATES, VEGAS-SUM,
VEGAS-MAX, LR and LR-PC tests, respectively, due to the
inclusion of non-causal SNPs for four combinations of LD blocks
(1 or 2) and low or high LD (r = 0.5 or r = 0.9). Other simulation
settings include: four causal SNPs, a combined relative risk of 2.00,
a total sample size of 4000 individuals, and a MAF of 30% for all
SNPs.
(PDF)

Figures S1–S5
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